Ratings Oculis Holding AG

Equities

Real-time Estimate Cboe BZX Other stock markets 09:35:28 2024-06-06 am EDT			5-day change	1st Jan Change
11.98 ^USD	+0.21%		+0.17%	+6.41%

May. 30	Oculis Holding AG Announces Board and Committee Appointments	CI
May. 30	Oculis Holding AG announced a financing transaction	CI

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

The prospective high growth for the next fiscal years is among the main assets of the company
Thanks to a sound financial situation, the firm has significant leeway for investment.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
The company's "enterprise value to sales" ratio is among the highest in the world.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the last few months, analysts have been revising downwards their earnings forecast.
Over the past four months, analysts' average price target has been revised downwards significantly.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

	1st Jan change	Capi.	ESG Refinitiv
OCULIS HOLDING AG	+6.41%	499M	-
MODERNA, INC.	+55.70%	59.34B	B-
LONZA GROUP AG	+42.55%	40.24B	A
IQVIA HOLDINGS INC.	-5.39%	39.88B	B
CELLTRION, INC.	-5.56%	28.55B	C
ICON PUBLIC LIMITED COMPANY	+16.46%	27.26B	B-
ALNYLAM PHARMACEUTICALS, INC.	-20.56%	19.23B	B
MEDPACE HOLDINGS, INC.	+33.03%	12.61B	C+
BIO-TECHNE CORPORATION	+2.72%	12.49B	B+
UNITED THERAPEUTICS CORPORATION	+25.85%	12.28B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality